Beyond Ozempic: Why Silicon Valley Is Turning to Experimental Peptides
Jasmine Sun on unregulated peptides moving from fringe biohacking to Silicon Valley mainstream, promising healing, focus, and optimization with little oversight
More Videos
Voya Financial Celebrates 10 Years of Meaningful Change
Voya Financial CEO Heather Lavellee marks 10 years of Voya Cares, spotlighting research and expanding financial access for Americans with disabilities.
The AI Paradox: Innovation vs. Risk in Financial Services
Kim Crawford Goodman, CEO of Smarsh, breaks down how financial firms are scaling AI while managing compliance, risk, and regulation in a changing landscape.
A New Direction for NYC? Inside Mamdani’s First 100 Days
Emma Goldberg, reporter at The New York Times, breaks down Mayor Mamdani’s first 100 days and what it means for NYC’s economy, businesses, and future.
The Business of Snack Nostalgia, A Favorite Returns!
Dan Fachner, CEO of J&J Snack Foods, shares how Dippin’ Dots is returning to stores and how the company is innovating for summer snack demand.
From Gas Pumps to Grocery Aisles: Inflation’s Grip Tightens
Elizabeth Renter, Senior Economist at NerdWallet, breaks down how inflation and oil price shocks are driving higher costs and squeezing consumers today.
Delivery Gets Personal: Inside the Next Wave of AI Robots
Ali Kashani, CEO of Serve Robotics, explains how Maggie is redefining delivery with AI, edge computing, and human-like interaction on city streets.
